Loading…
Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was formerly known as HDL Therapeutics, Inc. and changed its name to Esperion Therapeutics, Inc. in May 2008. The company was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $403M | $64M | $-23M | $-13M | 7.5% | 21.3% | - |
| 2024 | $332M | $8M | $-52M | $-24M | 13.3% | 185.7% | - |
| 2023 | $116M | $-150M | $-209M | $-135M | 46.0% | 54.1% | - |
| 2022 | $75M | $-176M | $-234M | $-175M | 72.2% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 75.47 | 116.33 | 332.31 | 403.13 |
| Cost Of Revenue | 26.97 | 43.27 | 68.60 | 129.22 |
| Gross Profit | 48.51 | 73.07 | 263.71 | 273.91 |
| Operating Expense | 228.01 | 228.63 | 209.31 | 213.64 |
| Operating Income | -179.50 | -155.56 | 54.40 | 60.27 |
| EBITDA | -176.35 | -150.11 | 7.57 | 63.87 |
| EBIT | -176.85 | -150.27 | 7.51 | 63.76 |
| Pretax Income | -233.66 | -209.25 | -51.74 | -20.84 |
| Tax Provision | 0 | 0 | 0 | 1.84 |
| Net Income | -233.66 | -209.25 | -51.74 | -22.68 |
| Net Income Common Stockholders | -233.66 | -209.25 | -51.74 | -22.68 |
| Total Expenses | 254.98 | 271.90 | 277.91 | 342.86 |
| Interest Expense | 56.81 | 58.98 | 59.25 | 84.60 |
| Research And Development | 118.93 | 86.11 | 46.24 | 47.85 |
| Selling General And Administration | 109.08 | 142.52 | 163.07 | 165.79 |
| Normalized EBITDA | -176.35 | -150.11 | 62.49 | 63.87 |
| Normalized Income | -233.66 | -209.25 | 3.17 | -22.68 |
| Basic EPS | -3.52 | -2.03 | -0.28 | -0.11 |
| Diluted EPS | -3.52 | -2.03 | -0.28 | -0.11 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0.21 |
| Total Unusual Items | 0 | 0 | -54.92 | 0 |
| Total Unusual Items Excluding Goodwill | 0 | 0 | -54.92 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -233.66 | -209.25 | -51.74 | -22.68 |
| Reconciled Depreciation | 0.50 | 0.16 | 0.06 | 0.10 |
| Reconciled Cost Of Revenue | 26.97 | 43.27 | 68.60 | 129.22 |
| Net Interest Income | -56.81 | -58.98 | -59.25 | -84.60 |
| Net Income From Continuing And Discontinued Operation | -233.66 | -209.25 | -51.74 | -22.68 |
| Total Operating Income As Reported | -179.50 | -155.56 | 54.40 | 60.27 |
| Diluted Average Shares | 66.41 | 103.11 | 187.18 | 207.87 |
| Basic Average Shares | 66.41 | 103.11 | 187.18 | 207.87 |
| Diluted NI Availto Com Stockholders | -233.66 | -209.25 | -51.74 | -22.68 |
| Net Income Including Noncontrolling Interests | -233.66 | -209.25 | -51.74 | -22.68 |
| Net Income Continuous Operations | -233.66 | -209.25 | -51.74 | -22.68 |
| Other Income Expense | 2.65 | 5.29 | -46.90 | 3.49 |
| Other Non Operating Income Expenses | 2.65 | 5.29 | 8.02 | 3.49 |
| Special Income Charges | 0 | 0 | -54.92 | 0 |
| Other Special Charges | 0 | 0 | 54.92 | 0 |
| Net Non Operating Interest Income Expense | -56.81 | -58.98 | -59.25 | -84.60 |
| Interest Expense Non Operating | 56.81 | 58.98 | 59.25 | 84.60 |
| Operating Revenue | 75.47 | 116.33 | 332.31 | 403.13 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Esperion Therapeutics, Inc.this co. | ESPR | $492M | - | -1.55 | 7.5% | 14.42 |
| Altimmune, Inc. | ALT | $511M | - | 1.30 | -39.2% | -1.10 |
| Tectonic Therapeutic, Inc. | TECX | $510M | - | 2.02 | -29.5% | -3.09 |
| Aquestive Therapeutics, Inc. | AQST | $503M | - | -14.67 | 248.9% | -5.90 |
| XOMA Royalty Corporation | XOMA | $497M |
| 28.08 |
| 5.79 |
| 37.8% |
| 38.75 |
| Entrada Therapeutics, Inc. | TRDA | $494M | - | 1.50 | -47.0% | -1.40 |
| ADC Therapeutics SA | ADCT | $481M | - | -2.56 | 76.7% | -6.25 |
| Fulcrum Therapeutics, Inc. | FULC | $476M | - | 1.36 | -21.5% | -1.75 |
| Verastem, Inc. | VSTM | $474M | - | 7.34 | -366.2% | -2.10 |
| Peer Median | - | 28.08 | 1.43 | -25.5% | -1.93 | |